Industry: Service & Software
Published Date: 2026-03-09
Pages: 129 Pages
Report ld: 6079550
Request Sample
Customized Report
Hemocompatibility Testing Service Market Size(US$)

CAGR 2026-2032
7.3%
Market Size,2032
USD 148
Million
Market Snapshot
Source: Secondary research, interviews with experts, and QYResearch analysis
The global Hemocompatibility Testing Service market was valued at US$ 91 million in 2025 and is anticipated to reach US$ 148 million by 2032, at a CAGR of 7.3% from 2026 to 2032.
Hemocompatibility testing service refers to a specialized analytical evaluation conducted to assess how biological materials, medical devices, or pharmaceuticals interact with blood components, ensuring they do not trigger adverse reactions such as thrombosis, hemolysis, inflammation, or immune responses. This service involves in vitro (test tube) and sometimes in vivo (animal model) assessments to measure parameters like blood cell adhesion, platelet activation, complement system activation, and coagulation factor disruption. It is crucial for the development and regulatory approval of medical products such as implants, catheters, artificial organs, or drug delivery systems, as non-hemocompatible materials can lead to life-threatening complications in patients. By simulating physiological conditions, these tests help manufacturers and researchers validate the safety of materials before human use, ensuring they integrate with the body’s circulatory system without compromising blood integrity or function.
The North American market for Hemocompatibility Testing Service is projected to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % over 2026–2032.
The Asia-Pacific market for Hemocompatibility Testing Service is projected to rise from US$ million in 2025 to US$ million by 2032, at a CAGR of % over 2026–2032.
The global market for Hemocompatibility Testing Service in Medical Device Development is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 to 2032.
Major global companies of Hemocompatibility Testing Service include Matexcel, Eurofins, Nelson Laboratories, LLC, Haemoscan, Measurlabs, STEMart, NAMSA, Lupine Medical, Eurolab, Nucro-Technics, etc. In 2025, the world's top three vendors accounted for approximately % of revenue.
This report delivers a comprehensive overview of the global Hemocompatibility Testing Service market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Hemocompatibility Testing Service. The Hemocompatibility Testing Service market size, estimates, and forecasts are provided in terms of revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.
The report segments the global Hemocompatibility Testing Service market comprehensively. Regional market sizes by Type, by Application, , and by player are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.
This report will assist Hemocompatibility Testing Service manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
MARKET SEGMENTATION
CHAPTER OUTLINE
Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, , etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
Chapter 2: Summarizes global and regional market size and outlines market dynamics and recent developments, including key drivers, restraints, challenges and risks for industry participants, and relevant policy analysis.
Chapter 3: Provides a detailed view of the competitive landscape for Hemocompatibility Testing Service companies, covering revenue share, development plans, and mergers and acquisitions.
Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify blue-ocean opportunities.
Chapter 5: Analyzes segments by Application, detailing the size and growth potential of each downstream segment to help readers identify blue-ocean opportunities.
Chapter 6–10: Regional deep dives (North America, Europe, Asia Pacific, Latin America, Middle East & Africa) broken down by country. Each chapter quantifies market size and growth potential by region and key countries, and outlines market development, outlook, addressable space, and capacity.
Chapter 11: Profiles key players, presenting essential information on leading companies, including product/ service offerings, revenue, gross margin, product introductions/portfolios, recent developments, etc.
Chapter 12: Key findings and conclusions of the report.
QYRESEARCH'S STRENGTHS
Unlike generic global market reports, this study combines macro-level industry trends with hyper-local operational intelligence, empowering data-driven decisions across the Compound Chocolate value chain, addressing:
We identify regional market threats and growth prospects to guide your overseas layout.
We adjust product portfolios in line with local consumption habits.
We unpack rivals’ operation strategies for scattered and highly concentrated industries.
We cover competition landscape, full supply chain and quantified market size data, and deliver tailor-made customized surveys to meet your unique business demands.
We own self-owned massive exclusive databases, backed by 19 years of global market research experience across thousands of sectors.
Our team operates 24 hours a day, 365 days a year, enabling ultra-fast report turnaround to respond to your research needs efficiently.
We integrate regional risk assessment, localized product optimization and competitor analysis to deliver actionable market strategies.
All data is cross-verified from multiple industry sources to deliver thorough, precise analysis that supports reliable corporate strategic decisions.
We provide responsive, dedicated after-sales support to resolve all follow-up inquiries about reports, data and industry interpretation.
TABLE OF CONTENTS
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Hemocompatibility Testing Service Market Size Growth Rate by Type: 2021 vs 2025 vs 2032
1.2.2 Hemolysis Testing
1.2.3 Complement Activation Testing
1.2.4 Platelet Activation Testing
1.2.5 Thrombogenicity Testing
1.2.6 Coagulation Testing
1.2.7 Others
1.3 Market by Application
1.3.1 Global Hemocompatibility Testing Service Market Growth by Application: 2021 vs 2025 vs 2032
1.3.2 Medical Device Development
1.3.3 Biomedical Materials Research
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Hemocompatibility Testing Service Market Perspective (2021–2032)
2.2 Global Hemocompatibility Testing Service Growth Trends by Region
2.2.1 Global Hemocompatibility Testing Service Market Size by Region: 2021 vs 2025 vs 2032
2.2.2 Hemocompatibility Testing Service Historic Market Size by Region (2021–2026)
2.2.3 Hemocompatibility Testing Service Forecasted Market Size by Region (2027–2032)
2.3 Hemocompatibility Testing Service Market Dynamics
2.3.1 Hemocompatibility Testing Service Industry Trends
2.3.2 Hemocompatibility Testing Service Market Drivers
2.3.3 Hemocompatibility Testing Service Market Challenges
2.3.4 Hemocompatibility Testing Service Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Hemocompatibility Testing Service Players by Revenue
3.1.1 Global Top Hemocompatibility Testing Service Players by Revenue (2021–2026)
3.1.2 Global Hemocompatibility Testing Service Revenue Market Share by Players (2021–2026)
3.2 Global Top Hemocompatibility Testing Service Players Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
3.3 Global Key Players Ranking by Hemocompatibility Testing Service Revenue
3.4 Global Hemocompatibility Testing Service Market Concentration Ratio
3.4.1 Global Hemocompatibility Testing Service Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Hemocompatibility Testing Service Revenue in 2025
3.5 Global Key Players of Hemocompatibility Testing Service Head Offices and Areas Served
3.6 Global Key Players of Hemocompatibility Testing Service, Products and Applications
3.7 Global Key Players of Hemocompatibility Testing Service, Date of General Availability (GA)
3.8 Mergers and Acquisitions, Expansion Plans
4 Hemocompatibility Testing Service Breakdown Data by Type
4.1 Global Hemocompatibility Testing Service Historic Market Size by Type (2021–2026)
4.2 Global Hemocompatibility Testing Service Forecasted Market Size by Type (2027–2032)
5 Hemocompatibility Testing Service Breakdown Data by Application
5.1 Global Hemocompatibility Testing Service Historic Market Size by Application (2021–2026)
5.2 Global Hemocompatibility Testing Service Forecasted Market Size by Application (2027–2032)
6 North America
6.1 North America Hemocompatibility Testing Service Market Size (2021–2032)
6.2 North America Hemocompatibility Testing Service Market Growth Rate by Country: 2021 vs 2025 vs 2032
6.3 North America Hemocompatibility Testing Service Market Size by Country (2021–2026)
6.4 North America Hemocompatibility Testing Service Market Size by Country (2027–2032)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Hemocompatibility Testing Service Market Size (2021–2032)
7.2 Europe Hemocompatibility Testing Service Market Growth Rate by Country: 2021 vs 2025 vs 2032
7.3 Europe Hemocompatibility Testing Service Market Size by Country (2021–2026)
7.4 Europe Hemocompatibility Testing Service Market Size by Country (2027–2032)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Ireland
8 Asia-Pacific
8.1 Asia-Pacific Hemocompatibility Testing Service Market Size (2021–2032)
8.2 Asia-Pacific Hemocompatibility Testing Service Market Growth Rate by Region: 2021 vs 2025 vs 2032
8.3 Asia-Pacific Hemocompatibility Testing Service Market Size by Region (2021–2026)
8.4 Asia-Pacific Hemocompatibility Testing Service Market Size by Region (2027–2032)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia & New Zealand
9 Latin America
9.1 Latin America Hemocompatibility Testing Service Market Size (2021–2032)
9.2 Latin America Hemocompatibility Testing Service Market Growth Rate by Country: 2021 vs 2025 vs 2032
9.3 Latin America Hemocompatibility Testing Service Market Size by Country (2021–2026)
9.4 Latin America Hemocompatibility Testing Service Market Size by Country (2027–2032)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Hemocompatibility Testing Service Market Size (2021–2032)
10.2 Middle East & Africa Hemocompatibility Testing Service Market Growth Rate by Country: 2021 vs 2025 vs 2032
10.3 Middle East & Africa Hemocompatibility Testing Service Market Size by Country (2021–2026)
10.4 Middle East & Africa Hemocompatibility Testing Service Market Size by Country (2027–2032)
10.5 Israel
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Matexcel
11.1.1 Matexcel Company Details
11.1.2 Matexcel Business Overview
11.1.3 Matexcel Hemocompatibility Testing Service Introduction
11.1.4 Matexcel Revenue in Hemocompatibility Testing Service Business (2021–2026)
11.1.5 Matexcel Recent Development
11.2 Eurofins
11.2.1 Eurofins Company Details
11.2.2 Eurofins Business Overview
11.2.3 Eurofins Hemocompatibility Testing Service Introduction
11.2.4 Eurofins Revenue in Hemocompatibility Testing Service Business (2021–2026)
11.2.5 Eurofins Recent Development
11.3 Nelson Laboratories, LLC
11.3.1 Nelson Laboratories, LLC Company Details
11.3.2 Nelson Laboratories, LLC Business Overview
11.3.3 Nelson Laboratories, LLC Hemocompatibility Testing Service Introduction
11.3.4 Nelson Laboratories, LLC Revenue in Hemocompatibility Testing Service Business (2021–2026)
11.3.5 Nelson Laboratories, LLC Recent Development
11.4 Haemoscan
11.4.1 Haemoscan Company Details
11.4.2 Haemoscan Business Overview
11.4.3 Haemoscan Hemocompatibility Testing Service Introduction
11.4.4 Haemoscan Revenue in Hemocompatibility Testing Service Business (2021–2026)
11.4.5 Haemoscan Recent Development
11.5 Measurlabs
11.5.1 Measurlabs Company Details
11.5.2 Measurlabs Business Overview
11.5.3 Measurlabs Hemocompatibility Testing Service Introduction
11.5.4 Measurlabs Revenue in Hemocompatibility Testing Service Business (2021–2026)
11.5.5 Measurlabs Recent Development
11.6 STEMart
11.6.1 STEMart Company Details
11.6.2 STEMart Business Overview
11.6.3 STEMart Hemocompatibility Testing Service Introduction
11.6.4 STEMart Revenue in Hemocompatibility Testing Service Business (2021–2026)
11.6.5 STEMart Recent Development
11.7 NAMSA
11.7.1 NAMSA Company Details
11.7.2 NAMSA Business Overview
11.7.3 NAMSA Hemocompatibility Testing Service Introduction
11.7.4 NAMSA Revenue in Hemocompatibility Testing Service Business (2021–2026)
11.7.5 NAMSA Recent Development
11.8 Lupine Medical
11.8.1 Lupine Medical Company Details
11.8.2 Lupine Medical Business Overview
11.8.3 Lupine Medical Hemocompatibility Testing Service Introduction
11.8.4 Lupine Medical Revenue in Hemocompatibility Testing Service Business (2021–2026)
11.8.5 Lupine Medical Recent Development
11.9 Eurolab
11.9.1 Eurolab Company Details
11.9.2 Eurolab Business Overview
11.9.3 Eurolab Hemocompatibility Testing Service Introduction
11.9.4 Eurolab Revenue in Hemocompatibility Testing Service Business (2021–2026)
11.9.5 Eurolab Recent Development
11.10 Nucro-Technics
11.10.1 Nucro-Technics Company Details
11.10.2 Nucro-Technics Business Overview
11.10.3 Nucro-Technics Hemocompatibility Testing Service Introduction
11.10.4 Nucro-Technics Revenue in Hemocompatibility Testing Service Business (2021–2026)
11.10.5 Nucro-Technics Recent Development
11.11 TÜV SÜD
11.11.1 TÜV SÜD Company Details
11.11.2 TÜV SÜD Business Overview
11.11.3 TÜV SÜD Hemocompatibility Testing Service Introduction
11.11.4 TÜV SÜD Revenue in Hemocompatibility Testing Service Business (2021–2026)
11.11.5 TÜV SÜD Recent Development
11.12 Eucerep
11.12.1 Eucerep Company Details
11.12.2 Eucerep Business Overview
11.12.3 Eucerep Hemocompatibility Testing Service Introduction
11.12.4 Eucerep Revenue in Hemocompatibility Testing Service Business (2021–2026)
11.12.5 Eucerep Recent Development
11.13 UL Solutions
11.13.1 UL Solutions Company Details
11.13.2 UL Solutions Business Overview
11.13.3 UL Solutions Hemocompatibility Testing Service Introduction
11.13.4 UL Solutions Revenue in Hemocompatibility Testing Service Business (2021–2026)
11.13.5 UL Solutions Recent Development
11.14 Level Biotechnology Inc.
11.14.1 Level Biotechnology Inc. Company Details
11.14.2 Level Biotechnology Inc. Business Overview
11.14.3 Level Biotechnology Inc. Hemocompatibility Testing Service Introduction
11.14.4 Level Biotechnology Inc. Revenue in Hemocompatibility Testing Service Business (2021–2026)
11.14.5 Level Biotechnology Inc. Recent Development
11.15 Cosmos Biomed Consulting
11.15.1 Cosmos Biomed Consulting Company Details
11.15.2 Cosmos Biomed Consulting Business Overview
11.15.3 Cosmos Biomed Consulting Hemocompatibility Testing Service Introduction
11.15.4 Cosmos Biomed Consulting Revenue in Hemocompatibility Testing Service Business (2021–2026)
11.15.5 Cosmos Biomed Consulting Recent Development
11.16 Charles River Laboratories
11.16.1 Charles River Laboratories Company Details
11.16.2 Charles River Laboratories Business Overview
11.16.3 Charles River Laboratories Hemocompatibility Testing Service Introduction
11.16.4 Charles River Laboratories Revenue in Hemocompatibility Testing Service Business (2021–2026)
11.16.5 Charles River Laboratories Recent Development
11.17 Ceshigo
11.17.1 Ceshigo Company Details
11.17.2 Ceshigo Business Overview
11.17.3 Ceshigo Hemocompatibility Testing Service Introduction
11.17.4 Ceshigo Revenue in Hemocompatibility Testing Service Business (2021–2026)
11.17.5 Ceshigo Recent Development
11.18 Kerbio
11.18.1 Kerbio Company Details
11.18.2 Kerbio Business Overview
11.18.3 Kerbio Hemocompatibility Testing Service Introduction
11.18.4 Kerbio Revenue in Hemocompatibility Testing Service Business (2021–2026)
11.18.5 Kerbio Recent Development
11.19 Weike Inspection Group
11.19.1 Weike Inspection Group Company Details
11.19.2 Weike Inspection Group Business Overview
11.19.3 Weike Inspection Group Hemocompatibility Testing Service Introduction
11.19.4 Weike Inspection Group Revenue in Hemocompatibility Testing Service Business (2021–2026)
11.19.5 Weike Inspection Group Recent Development
11.20 CTI
11.20.1 CTI Company Details
11.20.2 CTI Business Overview
11.20.3 CTI Hemocompatibility Testing Service Introduction
11.20.4 CTI Revenue in Hemocompatibility Testing Service Business (2021–2026)
11.20.5 CTI Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
TABLE OF FIGURES
List of Tables
List of Figures
KEY QUESTIONS ADDRESSED BY THE REPORT
Related Reports
The global Hemocompatibility Testing Service market is projected to grow from US$ 91 million in 2025 to US$ 148 million by 2032, at a CAGR of 7.3% (2026-2032), driven by critical product segments and diverse end‑use applications.
Published Date: 2026-03-12
Pages: 149
USD 4900.00
(Single User License)
The global Hemocompatibility Testing Service market size was US$ 91 million in 2025 and is forecast to reach a readjusted size of US$ 148 million by 2032 with a CAGR of 7.3% during the forecast period 2026-2032.
Published Date: 2026-03-12
Pages: 101
USD 4250.00
(Single User License)
The global market for Hemocompatibility Testing Service was estimated to be worth US$ 91 million in 2025 and is projected to reach US$ 148 million, growing at a CAGR of 7.3% from 2026 to 2032.
Published Date: 2026-03-09
Pages: 130
USD 3950.00
(Single User License)
The global market for Hemocompatibility Testing Service was valued at US$ 83.0 million in the year 2024 and is projected to reach a revised size of US$ 139 million by 2031, growing at a CAGR of 7.3% during the forecast period.
Published Date: 2025-06-07
Pages: 92
USD 2900.00
(Single User License)
The global market for Hemocompatibility Testing Service was estimated to be worth US$ 83.0 million in 2024 and is forecast to a readjusted size of US$ 139 million by 2031 with a CAGR of 7.3% during the forecast period 2025-2031.
Published Date: 2025-06-07
Pages: 134
USD 3950.00
(Single User License)
The global Hemocompatibility Testing Service market size was US$ 83.0 million in 2024 and is forecast to a readjusted size of US$ 139 million by 2031 with a CAGR of 7.3% during the forecast period 2025-2031.
Published Date: 2025-06-07
Pages: 107
USD 4250.00
(Single User License)
The global Hemocompatibility Testing Service market is projected to grow from US$ 91.0 million in 2025 to US$ 139 million by 2031, at a Compound Annual Growth Rate (CAGR) of 7.3% during the forecast period.
Published Date: 2025-06-07
Pages: 147
USD 4900.00
(Single User License)
The global Hemocompatibility Testing Service market is projected to grow from US$ 91 million in 2025 to US$ 148 million by 2032, at a CAGR of 7.3% (2026-2032), driven by critical product segments and diverse end‑use applications.
Published: 2026-03-12
Pages: 149
The global Hemocompatibility Testing Service market size was US$ 91 million in 2025 and is forecast to reach a readjusted size of US$ 148 million by 2032 with a CAGR of 7.3% during the forecast period 2026-2032.
Published: 2026-03-12
Pages: 101
The global market for Hemocompatibility Testing Service was estimated to be worth US$ 91 million in 2025 and is projected to reach US$ 148 million, growing at a CAGR of 7.3% from 2026 to 2032.
Published: 2026-03-09
Pages: 130
The global market for Hemocompatibility Testing Service was valued at US$ 83.0 million in the year 2024 and is projected to reach a revised size of US$ 139 million by 2031, growing at a CAGR of 7.3% during the forecast period.
Published: 2025-06-07
Pages: 92
The global market for Hemocompatibility Testing Service was estimated to be worth US$ 83.0 million in 2024 and is forecast to a readjusted size of US$ 139 million by 2031 with a CAGR of 7.3% during the forecast period 2025-2031.
Published: 2025-06-07
Pages: 134
The global Hemocompatibility Testing Service market size was US$ 83.0 million in 2024 and is forecast to a readjusted size of US$ 139 million by 2031 with a CAGR of 7.3% during the forecast period 2025-2031.
Published: 2025-06-07
Pages: 107
The global Hemocompatibility Testing Service market is projected to grow from US$ 91.0 million in 2025 to US$ 139 million by 2031, at a Compound Annual Growth Rate (CAGR) of 7.3% during the forecast period.
Published: 2025-06-07
Pages: 147
REPORT COVERAGE
DESCRIPTION
OVERVIEW
MARKET SEGMENTATION
CHAPTER OUTLINE
QYRESEARCH'S STRENGTHS
TABLE OF CONTENTS
TABLE OF FIGURES
RLEATED REPORTS
INTEREST IN THIS REPORT?
Get A Free Sample
Request For Quotation
OR
NEED A CUSTOMIZED REPORT?
Customized Report
Request Sample
Pre-Order Enquiry
Add to Cart
Buy Now